British pharmaceutical giant AstraZeneca has reported a significant 38% increase in pre-tax profits to £8.7 billion for 2024, driven by robust sales across its cancer, lung, and immunology treatments portfolio.
Healthcare8- Page
177Articles
Danish pharmaceutical giant Novo Nordisk has projected reduced growth for 2025 amidst mounting competition in the weight-loss drugs market from American rivals. The company, renowned for its obesity treatments Ozempic
British pharmaceutical giant GSK has announced its first share buyback programme in over a decade, committing £2 billion to the initiative whilst simultaneously upgrading its long-term sales projections. The FTSE
Spire Healthcare, the UK’s largest private healthcare provider, is witnessing unprecedented growth amid mounting NHS pressures. The FTSE 250-listed organisation has strategically positioned itself as a crucial partner in addressing
British care homes witnessed unprecedented transaction levels in 2024, with American investors leading the charge in one of the few property sectors still delivering robust rental growth. Data from property
Danish pharmaceutical giant Novo Nordisk, Europe’s most valuable listed company, has received a stern reprimand from the Prescription Medicines Code of Practice Authority (PMCPA) for systematically failing to disclose healthcare
The Sackler family and their pharmaceutical enterprise Purdue Pharma have reached a landmark £7.4 billion settlement over their involvement in the US opioid crisis, marking a significant development in one
A groundbreaking clinical trial at University College London (UCL) is poising to transform the landscape of alcohol misuse treatment through the utilisation of dimethyltryptamine (DMT), a potent psychedelic compound. The
British healthcare technology firm Cera has secured a landmark $150 million funding round, propelling the company to coveted unicorn status with a valuation exceeding $1 billion. The fundraising effort, combining
The British government is weighing a groundbreaking initiative that would permit private enterprises to monetise NHS patient data, marking a significant shift in healthcare data management. Labour leader Keir Starmer
British pharmaceutical giant GSK has struck a significant deal worth up to $1.15 billion to acquire IDRx, a Massachusetts-based biopharmaceutical company, strengthening its position in the oncology sector. The FTSE
Shares in Oxford Nanopore Technologies jumped 8.9 per cent today after the British gene sequencing innovator reported robust revenue growth and reaffirmed its path to profitability. The FTSE 250 company
In a significant move that marks the largest biotech acquisition since 2023, Johnson & Johnson has announced its agreement to purchase neuroscience drugmaker Intra-Cellular Therapies for £14.6 billion. The New
In a devastating blow to investor confidence, Moderna’s shares experienced a dramatic decline of up to 22 per cent on Monday following disappointing sales forecasts from the US biotech giant.
The struggling consumer healthcare company Alliance Pharma appears poised to exit London’s junior stock exchange following a £350 million takeover bid from activist investor Dbay Advisors. The Isle of Man-based
A groundbreaking series A funding round has positioned London-based Verdiva Bio at the forefront of the obesity treatment sector, securing an impressive $411 million investment. This remarkable achievement stands as
